New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress, the European Society of Cardiology (ESC) Congress 2014, on Sunday, Aug. 31 at 2:30 a.m. EDT.

Esaote is launching MyLab Gamma, a best-in-class, highly portable “green” cardiovascular ultrasound system at ESC Congress (European Society of Cardiology, Barcelona, Aug. 30-Sept. 3). 

August 22, 2014 — AliveCor announced the U.S. Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation (AF), the most common form of cardiac arrhythmia. Now with the AliveCor Heart Monitor, free AliveECG app and AFib Detector, a serious medical condition can be detected entirely using a mobile device.

Biotronik announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators).

Sunshine Heart Inc. announced that the current condition of a heart failure patient implanted with the C-Pulse System improved after six weeks of treatment, allowing him to attend his daughter's wedding.

August 21, 2014 — Christie Medical Holdings and Wolfson Children’s Hospital announced an agreement to replace all current peripheral vascular access visualization devices at the hospital with 17 VeinViewers through Christie's FreshStart program.

August 21, 2014 — diaDexus announced it has received notice from the U.S. Food and Drug Administration (FDA) that an administrative acceptance review was conducted on the traditional 510(k) submission of the PLAC Test for Lp-PLA2 Activity, and it was found to contain all of the necessary information needed to proceed with the substantive review.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now